US2011178282A1PendingUtilityA1
Methods and compositions for cancer therapy using a novel adenovirus
Individually held — no corporate assignee on recordPriority: Jul 9, 2003Filed: Oct 18, 2010Published: Jul 21, 2011
Est. expiryJul 9, 2023(expired)· nominal 20-yr term from priority
C12N 2799/022C12N 9/78A61P 35/00A61K 35/13C12N 15/62C12N 9/1211A61K 31/70C07H 21/04A61K 48/00Y02A50/30
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention comprises a novel virus that can kill mammalian cancer cells efficiently. The virus produces a novel protein that converts two non-toxic prodrugs into potent chemotherapeutic agents. These chemotherapeutic agents are produced locally and help the virus kill the cancer cells as well as sensitize them to radiation. In preclinical studies, the virus has proven effective at killing a variety of mammalian cancer cells either alone or when combined with prodrug therapy and/or radiation therapy. The invention may provide a safe and effective treatment for human cancer.
Claims
exact text as granted — not AI-modified1 . An isolated polynucleotide comprising a nucleotide sequence of a yeast cytosine deaminase/mutant SR 39 herpes simplex virus type 1 thymidine kinase fusion gene, comprising the nucleotide sequence of SEQ ID NO: 4.
2 .- 4 . (canceled)Join the waitlist — get patent alerts
Track US2011178282A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.